格隆汇9月11日｜据SEC文件披露，制药巨头艾伯维就瑞福(Rinvoq)专利诉讼与仿制药商达成和解。艾伯 维还称，乌帕替尼片在2037年4月前不会面临仿制药竞争。 ...

Core Insights - The article discusses the urgent need for effective treatments for immune skin diseases like vitiligo and rosacea, highlighting the lack of approved targeted therapies globally [1][2][3] - CKBA, an innovative drug derived from traditional Chinese medicine, is presented as a potential breakthrough in treating vitiligo, particularly for children aged 2 to 12 [5][6] - The article emphasizes the complexity of vitiligo's treatment landscape, with high recurrence rates and limited effective long-term therapies currently available [4][5] Group 1: Current Treatment Landscape - Vitiligo affects approximately 12 million children in China, with no approved new drugs for this demographic globally [2] - Current treatment options are limited to off-label use of corticosteroids and JAK inhibitors, with only 1.5% of ruxolitinib cream approved for patients over 12 in the U.S. [2][3] - The complexity of vitiligo's pathophysiology involves multiple targets and signaling pathways, complicating treatment efforts [2][3] Group 2: CKBA's Potential - CKBA is the first drug targeting T-cell fatty acid metabolism pathways, showing promising results in early clinical trials [3][5] - Initial Phase II trial results indicate that high-dose CKBA cream significantly improved vitiligo scores compared to placebo, with 36% of patients showing varying degrees of repigmentation [3][5] - If successful in Phase III trials, CKBA could become the first drug to provide both treatment and maintenance efficacy for vitiligo [5][6] Group 3: Broader Implications and Future Research - The article notes that CKBA may also have potential applications in treating other conditions, such as rosacea and Alzheimer's disease, indicating a broader therapeutic scope [7][9] - The research pipeline for Alzheimer's disease is expanding, with various drugs showing promise, including those targeting amyloid and tau proteins [8][9] - The exploration of immune-modulating drugs across different diseases highlights the potential for innovative treatments in previously challenging areas [9]